FDA panel won't back Regeneron's (REGN) Arcalyst for the treatment of gout
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Join SI Premium – FREE
FDA panel won't back Regeneron's (Nasdaq: REGN) Arcalyst for the treatment of gout. Vote was unanimous at 11-0.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus drug combo shows 33% three-year survival in colorectal cancer
- BiomX announces 1-for-10 reverse stock split effective Sept. 9
- Peabody Energy COO to shift to consulting role starting 2027
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
